KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Treasury Shares (2021 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Treasury Shares for 5 consecutive years, with $12.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Treasury Shares rose 258.82% year-over-year to $12.2 million, compared with a TTM value of $12.2 million through Sep 2025, up 258.82%, and an annual FY2024 reading of $6.1 million, down 21.86% over the prior year.
  • Treasury Shares was $12.2 million for Q3 2025 at Aurinia Pharmaceuticals, up from $11.2 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $14.8 million in Q2 2021 and bottomed at $347000.0 in Q4 2021.
  • Average Treasury Shares over 5 years is $6.6 million, with a median of $6.1 million recorded in 2024.
  • The sharpest move saw Treasury Shares crashed 86.78% in 2022, then skyrocketed 918.18% in 2025.
  • Year by year, Treasury Shares stood at $347000.0 in 2021, then surged by 470.61% to $2.0 million in 2022, then skyrocketed by 294.29% to $7.8 million in 2023, then dropped by 21.86% to $6.1 million in 2024, then skyrocketed by 100.0% to $12.2 million in 2025.
  • Business Quant data shows Treasury Shares for AUPH at $12.2 million in Q3 2025, $11.2 million in Q2 2025, and $5.8 million in Q1 2025.